RAYDIAX GmbH

Key People

• Dr. Thomas Hoffmann - CEO and Co-Founder
• Tim Pfeiffer, Ph.D. - CTO and Co-Founder
• Roy Rothenberg - CFO
• Benjamin Fritsch - Head of Hardware
• Robert Frysch - Head of Software
• Andr Mewes - Head of Software
• Sebastian Gugel - Head of Medical Affairs

Assessment

Team

Aspect: First-time 10+ yrs
Summary: The founding team comprises individuals with over a decade of experience in medical technology and related fields.

The leadership team, including Dr. Thomas Hoffmann and Tim Pfeiffer, Ph.D., brings significant expertise in medical technology, enhancing the company's potential for innovation and market penetration.

Clinical Need

Aspect: Strong
Summary: RAYDIAX addresses a significant need for advanced imaging in minimally invasive cancer treatments.

The TACT system's ability to provide high-quality 3D imaging and large-area 2D angiography enhances the precision and safety of minimally invasive procedures, fulfilling a strong clinical need.

Competition

Aspect: Somewhat crowded
Summary: The market for imaging systems in minimally invasive interventions has several established players.

While the TACT system offers unique features, the presence of other imaging technologies in the market may pose challenges in differentiating and capturing market share.

Technical Challenge

Aspect: Moderate
Summary: Developing a hybrid imaging system like TACT involves moderate technical complexity.

Integrating high-quality 3D CT imaging with 2D angiography requires careful engineering and validation, but the team's expertise suggests these challenges are surmountable.

Patent

Aspect: Applied
Summary: RAYDIAX has applied for patents to protect its technology.

Securing patents for the TACT system will provide RAYDIAX with intellectual property protection, enhancing its market exclusivity and valuation.

Financing

Aspect: Well-funded
Summary: RAYDIAX has secured significant funding to advance its product development.

The 3.5 million raised in October 2023, including investments from HTGF and bmp Ventures, provides the necessary capital to progress the TACT system towards market readiness.

Regulatory

Aspect: Running FIH
Summary: RAYDIAX is in the process of conducting first-in-human trials.

Conducting first-in-human trials is a critical step towards regulatory approval, but it involves inherent risks and uncertainties that the company must manage effectively.

Opportunity Rollup

Odds of Success

3.65

Peak Market Share

5.35

Segment CAGR

2.9%

Market Segment

Diagnostic Imaging

Market Sub Segment

Interventional Radiology

Key Takeaway

RAYDIAX's innovative TACT system addresses a significant clinical need in minimally invasive cancer treatments, supported by a strong team and substantial funding, positioning the company for potential success despite competitive and regulatory challenges.